FDA Approves MDRNA's Generic Osteoporosis Nasal Spray

Shares of MDRNA Inc. (Nasdaq: MRNA) leaped $1.22 to $2.76 after the FDA approved its generic osteoporosis nasal spray.



About this Entry

This page contains a single entry by published on June 9, 2009 10:06 AM.

Positive Trial Results For Arena Pharmaceuticals was the previous entry in this blog.

Marvell Technology Upgraded is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12